Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$73.02
-3.8%		$67.98
$25.34
▼
$109.00
$2.47B1.14686,598 shs828,355 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$48.22
+0.2%		$38.53
$15.86
▼
$49.67
$2.36B1.57838,407 shs458,057 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
0.00%-4.52%+8.90%+3.40%+183.90%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+2.68%+20.55%+67.55%+139.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$73.02
-3.8%		$67.98
$25.34
▼
$109.00
$2.47B1.14686,598 shs828,355 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$48.22
+0.2%		$38.53
$15.86
▼
$49.67
$2.36B1.57838,407 shs458,057 shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
0.00%-4.52%+8.90%+3.40%+183.90%
Urogen Pharma stock logo
URGN
Urogen Pharma
0.00%+2.68%+20.55%+67.55%+139.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.75
Moderate Buy$150.00105.42% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
2.82
Moderate Buy$48.781.16% Upside

Current Analyst Ratings Breakdown

Latest NKTR and URGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$42.00 ➝ $58.00
8/6/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $75.00
8/5/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $60.00
7/22/2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$153.00
7/21/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $42.00
7/17/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/16/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$40.00 ➝ $50.00
7/15/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$44.00
7/9/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/9/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/3/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$55.23M44.67N/AN/A$4.41 per share16.56
Urogen Pharma stock logo
URGN
Urogen Pharma
$109.79M21.47N/AN/A($2.25) per share-21.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$164.08M-$6.70N/AN/AN/A-287.84%-37.87%-25.67%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$153.49M-$1.98N/A13.82N/A-51.73%N/A-43.79%N/A

Latest NKTR and URGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$1.97-$1.23+$0.74-$1.23$10.43 million$10.13 million
8/5/2026Q2 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.2650-$0.28-$0.0150-$0.28$63.55 million$72.46 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
10.42
10.21
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
3.80
3.41

Institutional Ownership

CompanyInstitutional Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2.50%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22033.79 million32.94 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20048.88 million46.54 millionOptionable

Recent News About These Companies

California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN
August 15 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-grows-stock-holdings-in-urogen-pharma-urgn-2026-08-15/
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
August 14 at 1:01 PM  |  zacks.comhttps://www.zacks.com/stock/news/2975200/are-you-looking-for-a-top-momentum-pick-why-urogen-pharma-urgn-is-a-great-choice?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_10-2975200
UroGen (URGN) Q2 2026 Earnings Call Transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/urogen-urgn-q2-2026-earnings-181544359.html
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - Time to Buy?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-hits-new-1-year-high-time-to-buy-2026-08-12/
Q3 EPS Estimates for Urogen Pharma Lifted by HC Wainwright
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-eps-estimates-for-urogen-pharma-lifted-by-hc-wainwright-2026-08-10/
UroGen Pharma (URGN) Earnings Put Its Fair Value Debate Back In Focus
August 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/urogen-pharma-urgn-earnings-put-170902275.html
Urogen Pharma $URGN Shares Purchased by Hennion & Walsh Asset Management Inc.
August 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-urogen-pharma-urgn-shares-purchased-by-hennion-walsh-asset-management-inc-2026-08-09/
Urogen Pharma (NASDAQ:URGN) Price Target Raised to $75.00
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949721
UroGen Pharma Ltd URGN
August 8, 2026  |  morningstar.comM
Urogen Pharma (NASDAQ:URGN) Given New $75.00 Price Target at HC Wainwright
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-given-new-7500-price-target-at-hc-wainwright-2026-08-06/
Urogen Pharma (NASDAQ:URGN) Hits New 1-Year High - What's Next?
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-hits-new-1-year-high-whats-next-2026-08-06/
Urogen Pharma Q2 Earnings Call Highlights
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-q2-earnings-call-highlights-2026-08-05/
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931074-urogen-pharma-ltd-urgn-q2-2026-earnings-call-transcript
Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-announces-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-05/
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/urogen-reports-50-4-million-of-zusduri-revenue-and-provides-second-quarter-2026-financial-results-and-highlights-1036412806
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-stock-price-up-91-heres-why-2026-08-05/
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968630/urogen-pharma-urgn-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968630
Swiss National Bank Makes New $1.40 Million Investment in Urogen Pharma $URGN
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-swiss-national-bank-makes-new-140-million-investment-in-urogen-pharma-urgn-2026-08-01/
UroGen Pharma (NASDAQ:URGN) Approaches A Defining Results Update
July 31, 2026  |  kalkinemedia.comK
Urogen Pharma (URGN) to Announce Quarterly Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-urgn-to-announce-quarterly-earnings-on-thursday-2026-07-30/
Healthcare of Ontario Pension Plan Trust Fund Sells 738,026 Shares of Urogen Pharma $URGN
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-healthcare-of-ontario-pension-plan-trust-fund-sells-738026-shares-of-urogen-pharma-urgn-2026-07-30/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$73.02 -2.90 (-3.82%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$73.26 +0.24 (+0.33%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$48.22 +0.10 (+0.21%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$48.22 0.00 (0.00%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas